Immunotherapy with recombinant human IL-2 (rHuIL-2) after autologous stem cell transplantation (ASCT) for high-risk neuroblastoma (HR-NB).

被引：0
|
作者：
Pession, A
Prete, A
Locatelli, F
Melchionda, F
Messina, C
Bonetti, F
Alvisi, P
Cordero, L
Rondelli, R
Rabusin, M
Favre, BC
Arrighini, A
Paolucci, P
Millanaccio, C
Bernardi, D
Paolucci, G
机构：
[1] Dept Pediat, Bologna, Italy
[2] Univ Pavia, Dept Pediat, I-27100 Pavia, Italy
[3] Univ Turin, Dept Pediat, I-10124 Torino, Italy
[4] Univ Padua, Dept Pediat, Padova, Italy
[5] Dept Pediat, Genova, Italy
[6] Dept Pediat, Trieste, Italy
[7] Dept Pediat, Pisa, Italy
[8] Dept Pediat, S Giovanni Rotondo, Italy
[9] Univ Brescia, Dept Pediat, Brescia, Italy
来源：
BONE MARROW TRANSPLANTATION | 1998年 / 21卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
780
引用
收藏
页码：S222 / S222
页数：1
相关论文
共 50 条
  • [21] Autologous Stem-Cell Transplantation for High-Risk Neuroblastoma: Historical and Critical Review
    Mora, Jaume
    CANCERS, 2022, 14 (11)
  • [22] Immunotherapy for high-risk neuroblastoma: allogeneic stem cell transplantation and recipient leucocyte infusion
    de Casterle, I. Dierckx
    Rutgeerts, O.
    Fevery, S.
    Lenaerts, C.
    Waer, M.
    Billiau, A.
    Sprangers, B.
    ANNALS OF ONCOLOGY, 2015, 26 : 11 - 11
  • [23] IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation
    Koehl, U
    Sörensen, J
    Esser, R
    Zimmermann, S
    Grüttner, HP
    Tonn, T
    Seidl, C
    Seifried, E
    Klingebiel, T
    Schwabe, D
    BLOOD CELLS MOLECULES AND DISEASES, 2004, 33 (03) : 261 - 266
  • [24] Naxitamab, a new generation anti-GD2 monoclonal antibody (mAb) for treatment of relapsed/refractory high-risk neuroblastoma (HR-NB).
    Mora, Jaume
    Chan, Godfrey Chi-Fung
    Morgenstern, Daniel A.
    Nysom, Karsten
    Bear, Melissa K.
    Dalby, Lene Worsaae
    Lisby, Steen
    Kushner, Brian H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [25] A randomized phase III trial of myeloablative autologous peripheral blood stem cell (PBSC) transplant (ASCT) for high-risk neuroblastoma (HR-NB) employing immunomagnetic purged (P) versus unpurged (UP) PBSC: A Children's Oncology Group study
    Kreissman, S. G.
    Villablanca, J. G.
    Seeger, R. C.
    Grupp, S. A.
    London, W. B.
    Maris, J. M.
    Park, J. R.
    Cohn, S. L.
    Matthay, K. K.
    Reynolds, C. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [26] Newly Diagnosed Myeloma (MM) Patients (Pts) with High-Risk (HR) Cytogenetics By FISH: Is There a Role for Tandem Autologous Stem Cell Transplantation (ASCT)?
    Farshchi-Zarabi, Sara
    Parmar, Gurdeep
    Masih-Khan, Esther
    Farooki, Sophia
    Chen, Christine
    Kukreti, Vishal
    Prica, Anca
    Tiedemann, Rodger
    Trudel, Suzanne
    Reece, Donna
    BLOOD, 2015, 126 (23)
  • [27] Autologous stem cell transplantation (ASCT) for multiple myeloma followed by immunomodulation with interferon-2α (IFN-2α) and interleukin-2 (IL-2).
    Oliveira, JSR
    Cecyn, KZ
    Faria, RMD
    Parisio, K
    Ribeiro, APMR
    Gomes, LS
    Juliane, JMF
    Raineri, G
    BLOOD, 2001, 98 (11) : 397B - 397B
  • [28] The Role of Autologous Stem-Cell Transplantation in High-Risk Neuroblastoma Consolidated by anti-GD2 Immunotherapy. Results of Two Consecutive Studies
    Mora, Jaume
    Castaneda, Alicia
    Flores, Miguel A.
    Santa-Maria, Vicente
    Garraus, Moira
    Gorostegui, Maite
    Simao, Margarida
    Perez-Jaume, Sara
    Mane, Salvador
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [29] Anti-GD2 antibody-containing immunotherapy postconsolidation therapy for people with high-risk neuroblastoma treated with autologous haematopoietic stem cell transplantation
    Peinemann, Frank
    van Dalen, Elvira C.
    Enk, Heike
    Tytgat, Godelieve A. M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2019, (04):
  • [30] Autologous Stem-Cell Transplant (ASCT) for High-Risk Neuroblastoma: Achieving Cure with Low-Cost Innovations
    Jain, R.
    Hans, R.
    Totadri, S.
    Trehan, A.
    Sharma, R. R.
    Menon, P.
    Kapoor, R.
    Saxena, A.
    Mittal, B. R.
    Bhatia, P.
    Kakkar, N.
    Srinivasan, R.
    Rajwanshi, A.
    Varma, N.
    Samujh, R.
    Marwaha, N.
    Bansal, D.
    PEDIATRIC BLOOD & CANCER, 2018, 65 : S237 - S237
12345